MITSUBISHI-HITACHI-POWER
Mitsubishi Hitachi Power Systems, Ltd. (MHPS) has begun commissioning of T-Point 2, its new combined cycle power plant validation facility at Takasago Works in Hyogo Prefecture, Japan. Replacing the iconic T-Point, the facility will accelerate MHPS’ industry-leading technology and enable more robust validation of advanced-class gas turbines (ACGTs) such as the 1650°C-class JAC model and 1700°C-class ultrahigh-temperature models. Like its predecessor, T-Point 2 stands apart as the only facility in the world that performs full-scale long-term reliability verification for gas turbines. Connected to the actual grid, it is the only plant of its type in the world to function as both a technology demonstrator and an electric power producer and supplier. Also housed within Takasago Works are centers for R&D, design, manufacturing, and short-term component testing.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200401005834/en/
“Through the years, we have proven our ability to develop and manufacture the most cutting-edge solutions for the power generation industry,” said Mr. Ken Kawai, President and CEO, MHPS. “Building on the legacy of the original T-Point, T-Point 2 will enable us to widen our footprint as the preferred solutions partner to meet ever-changing power generation requirements around the world.”
Engineering the next generation of gas turbines
Once commercial operations begin in July 2020, T-Point 2 is expected to achieve power output of over 566 MW (60Hz), with nearly 64% efficiency, 99.5% reliability and a world-first turbine inlet temperature of 1650°C – raising industry standards for gas turbine combined cycle performance globally. This improved performance is possible due to the advanced engineering of the upgraded J-Series Air-Cooled (JAC) model, which is the first gas turbine being validated at T-Point 2.
The new facility features a triple-casing steam turbine, augmenting overall system efficiency through a multiplier effect with the JAC gas turbine. This greater efficiency reduces carbon emissions and heat loss, significantly reducing the environmental impact of T-Point 2.
“The prototype validation system established by MHPS has given our customers the clear assurance that they are receiving the highest caliber and most reliable energy solutions in the market,” said Mr. Junichiro Masada, Senior Vice President and Senior General Manager of Gas Turbine Technology & Products Integration Division, MHPS. “The launch of T-Point 2 is testament to MHPS’ commitment to deliver industry-leading power generation technology and customer service underpinned by best-in-class methods for performance and durability verification.”
MHPS will use the facility to conduct validation of the next-generation 1700°C-class ultrahigh-temperature gas turbines, steam turbine upgrades, air-cooled condenser technology, generators, and static frequency converters.
Bringing power generation to the digital age
Work is underway to install and train advanced artificial intelligence technology at T-Point 2, which will feature the MHPS-TOMONI®
suite of digital solutions. During the 8,000 hour durability demonstration period, MHPS will also be training its AI apps, allowing T-Point 2 to eventually become the world’s first autonomous combined cycle power plant. This will catapult power generation into a future where digital technologies are fully integrated into plant operations, allowing plant owners to leverage data to optimize performance, enable condition-based predictive maintenance for equipment, selectively automate operation and maintenance (O&M) decision-making, and reduce risk.
With these building blocks, MHPS will remotely monitor and manage total plant performance; remotely operate the plant in coordination with grid and fleet-wide energy management objectives; and utilize sensor and control system data to make smarter operation decisions in real time. MHPS-TOMONI® solutions powered by advanced technologies such as artificial intelligence and machine learning will enable MHPS to automate O&M decision-making to maximize the profitability of existing and future GTCC plants.
About Mitsubishi Hitachi Power Systems, Ltd.
Mitsubishi Hitachi Power Systems, Ltd. (MHPS), headquartered in Yokohama, Japan, is a joint venture formed in February 2014 by Mitsubishi Heavy Industries, Ltd. and Hitachi, Ltd. integrating their operations in thermal power generation systems and other related businesses. MHPS today ranks among the world’s leading suppliers of equipment and services to the power generation market, backed by 100 billion yen in capital and approximately 20,000 employees worldwide. The Company’s products include GTCC (gas turbine combined-cycle) and IGCC (integrated coal gasification combined-cycle) power plants, gas/coal/oil-fired (steam) power plants, boilers, generators, gas and steam turbines, geothermal power plants, AQCS (air quality control systems), power plant peripheral equipment and solid-oxide fuel cells (SOFC). For more information, please visit the Company's website at https://www.mhps.com
. Follow us at https://twitter.com/MHPS_Global
, or http://www.linkedin.com/showcase/mhps
View source version on businesswire.com: https://www.businesswire.com/news/home/20200401005834/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
